Bipolar Radiofrequency Ablation of Atrial Tachycardia Originating From RAA via Pericardium Pathway-A Case Report.

Pacing Clin ElectrophysiolApr 2, 2026 (epub)
Case ReportCardiology

Liang Xiong, Lili Qiu, Xiaowen Xie et al.

✦ AI-curated · Sources linked

Case in brief

The report describes a patient with atrial tachycardia originating from the right atrial appendage (RAA). Because catheter ablation of RAA tachycardia can be challenging in the setting of the appendage’s complex anatomy, the team used bipolar radiofrequency ablation via a pericardial pathway. The procedure successfully treated the tachycardia. The abstract does not provide further patient characteristics or clinical follow-up details.

What made this case unusual

Bipolar radiofrequency ablation was delivered to an RAA tachycardia origin via a pericardial pathway, addressing the anatomical challenge associated with conventional ablation in this location.

Diagnostic / clinical pearl

For tachycardia arising from the anatomically complex RAA, bipolar radiofrequency ablation via a pericardial pathway may be a successful approach in an individual case.

Source

PubMed · PMID 41924977

Published in Pacing Clin Electrophysiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.